BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics.
作者信息
Pan Rongqing Aaron, Wang Youzhen, Qiu Shumei, Villalobos-Ortiz Mariana, Ryan Jeremy, Morris Erick, Halilovic Ensar, Letai Anthony
机构信息
Bone Marrow Transplantation Center of the First Affiliated Hospital and Institute of Hematology and Department of Immunology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215.
Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA 02139.
出版信息
Haematologica. 2024 Apr 1;109(4):1253-1258. doi: 10.3324/haematol.2023.283060.
Abstract
摘要
相似文献
1
BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics.
Haematologica. 2024 Apr 1;109(4):1253-1258. doi: 10.3324/haematol.2023.283060.
2
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.
Cell Death Dis. 2020 Aug 15;11(8):634. doi: 10.1038/s41419-020-02887-y.
3
BH3 mimetics: status of the field and new developments.
Mol Cancer Ther. 2013 Sep;12(9):1691-700. doi: 10.1158/1535-7163.MCT-13-0058. Epub 2013 Aug 23.
4
Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156.
5
Impact of BH3-mimetics on Human and Mouse Blood Leukocytes: A Comparative Study.
Sci Rep. 2020 Jan 14;10(1):222. doi: 10.1038/s41598-019-57000-x.
6
BH3-mimetics--the solution to chemoresistance?
Leuk Lymphoma. 2009 Jul;50(7):1069-72. doi: 10.1080/10428190903015644.
7
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
Mol Cancer Ther. 2016 Sep;15(9):2011-7. doi: 10.1158/1535-7163.MCT-16-0031. Epub 2016 Aug 17.
8
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Blood. 2021 May 20;137(20):2721-2735. doi: 10.1182/blood.2020010167.
9
BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Anticancer Res. 2014 Nov;34(11):6423-30.
10
Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
Mol Cancer Ther. 2021 Aug;20(8):1469-1480. doi: 10.1158/1535-7163.MCT-20-0887. Epub 2021 Jun 4.
引用本文的文献
1
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins.
Cell Death Differ. 2025 Apr 9. doi: 10.1038/s41418-025-01487-7.
2
Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo.
BMC Cancer. 2024 Nov 4;24(1):1350. doi: 10.1186/s12885-024-13088-7.
本文引用的文献
1
Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis.
Cell. 2022 Apr 28;185(9):1521-1538.e18. doi: 10.1016/j.cell.2022.03.030. Epub 2022 Apr 20.
2
Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens.
Cancer Discov. 2022 Feb;12(2):290-292. doi: 10.1158/2159-8290.CD-21-1498.
3
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.
Nat Rev Cancer. 2022 Jan;22(1):45-64. doi: 10.1038/s41568-021-00407-4. Epub 2021 Oct 18.
4
Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor.
J Med Chem. 2020 Nov 25;63(22):13762-13795. doi: 10.1021/acs.jmedchem.0c01234. Epub 2020 Nov 4.
5
BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics.
Cell Death Differ. 2020 Mar;27(3):999-1007. doi: 10.1038/s41418-019-0391-9. Epub 2019 Jul 22.
6
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.
Nat Rev Mol Cell Biol. 2019 Mar;20(3):175-193. doi: 10.1038/s41580-018-0089-8.
7
Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.
Cancer Cell. 2017 Jan 9;31(1):142-156. doi: 10.1016/j.ccell.2016.11.011. Epub 2016 Dec 22.
8
Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.
Oncotarget. 2016 Mar 8;7(10):11500-11. doi: 10.18632/oncotarget.7204.
9
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.
Cell. 2015 Feb 26;160(5):977-989. doi: 10.1016/j.cell.2015.01.042.
10
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.
Zotero 插件